Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation

Andrew S. Felts,† Alice L. Rodriguez,† Anna L. Blobaum,† Ryan D. Morrison,† Brittney S. Bates,† Analisa Thompson Gray,† Jerri M. Rook,† Mohammed N. Tantawy,∥ Frank W. Byers,† Sichen Chang,† Daryl F. Venable,† Vincent B. Luscombe,† Gilles D. Tamagnan,‡ Colleen M. Niswender,† J. Scott Daniels,† Carrie K. Jones,† P. Jeffrey Conn,† Craig W. Lindsley,†,§ and Kyle A. Emmitte*†

†Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology and §Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States
∥Department of Radiology and Radiological Sciences, Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
‡Molecular NeuroImaging, a Division of inviCRO, New Haven, Connecticut 06510, United States

ABSTRACT: Preclinical evidence in support of the potential utility of mGlu5 NAMs for the treatment of a variety of psychiatric and neurodegenerative disorders is extensive, and multiple such molecules have entered clinical trials. Despite some promising results from clinical studies, no small molecule mGlu5 NAM has yet to reach market. Here we present the discovery and evaluation of N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (27, VU0424238), a compound selected for clinical evaluation. Compound 27 is more than 900-fold selective for mGlu5 versus the other mGlu receptors, and binding studies established a Ki value of 4.4 nM at a known allosteric binding site. Compound 27 had a clearance of 19.3 and 15.5 mL/min/kg in rats and cynomolgus monkeys, respectively. Imaging studies using a known mGlu5 PET ligand demonstrated 50% receptor occupancy at an oral dose of 0.8 mg/kg in rats and an intravenous dose of 0.06 mg/kg in baboons.

INTRODUCTION

The metabotropic glutamate (mGlu) receptors are an eight-membered family of class C G protein-coupled receptors (GPCRs) that are activated by l-glutamic acid, the major excitatory neurotransmitter of the mammalian central nervous system (CNS). Further stratification of the mGlu receptors is made based on a variety of considerations, including structure, downstream signaling partners, and pharmacology. Whereas group I mGlu receptors (mGlu1 and mGlu5) are found in postsynaptic locations and couple via Gq to the activation of phospholipase C (PLC), both group II (mGlu2−3) and group III (mGlu4 and mGlu6−8) receptors are found mainly in presynaptic locations and couple via Gi/Go to the inhibition of adenyl cyclase activity. Common to all mGlu receptors are a seven transmembrane (7TM) α-helical domain that connects to a large bilobed extracellular amino-terminal domain, sometimes termed the “venus fly trap (VFT)” domain. Located within this VFT domain is the binding site for the native ligand; however, allosteric binding sites for small molecules have thus far been confined to the transmembrane domain. The structural and functional properties of the mGlu receptors have been reviewed extensively.1,2

In the search for compounds that are sufficiently selective for individual mGlu receptor subtypes, we have found allosteric modulation to be a successful approach. In fact, in many cases, such a strategy can be employed for the design of both positive allosteric modulators (PAMs) and negative allosteric modu-
lators (NAMs) of the same receptor. Among the most actively investigated and advanced areas within this field is that of mGlu5 NAMs. Potential therapeutic applications for small molecule mGlu5 NAMs are extensive and include addiction, Alzheimer’s disease (AD), anxiety, autism spectrum disorder (ASD), fragile X syndrome (FXS), the levodopa-induced dyskinesia (LID) experienced by many patients with Parkinson’s disease (PD), major depressive disorder (MDD), and obsessive-compulsive disorder (OCD). Much of the preclinical work that has served to establish mGlu5 antagonism as an exciting new mechanism for targeting these various conditions has been conducted with two related tool compounds, methyl-6-(phenylethynyl)-pyridine (1, MPEP) and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (2, MTEP) (Figure 1). Both compounds are structurally similar disubstituted alkynes, a motif that has been exploited for the design of several other highly optimized mGlu5 NAM compounds. While results from clinical studies have been reported with nonalkyne based mGlu5 NAMs such as 3 (fenobam) and 4 (AZD9272), and 5 (AZD2066), the most highly studied and advanced clinical compounds are three alkyne mGlu5 NAMs: 6 (mavoglurant), 7 (baminglurant), and 8 (dipraglurant) (Figure 1). Still, failures to reach primary clinical end points with 6,7,8 and 7,8 point to the continued need for highly optimized mGlu5 NAMs. It should be noted that a recent report from Pfizer has described cutaneous toxicities in cynomolgus monkey toxicity studies with three structurally related nonalkyne based mGlu5 NAMs. Given that other mGlu5 NAMs that are not structurally related to the Pfizer compounds have been used in long-term, repeat dose studies in nonhuman primates (NHPs) and humans without notes of a similar significant toxicity, it seems reasonable that such effects are not endemic to the mechanism. Still, these results make a compelling argument for using cynomolgus monkeys as the nonrodent species for toxicology studies in the event that our conclusion is incorrect.

Alkynes are potentially reactive functional groups. Pfizer has reported an instance of biliary epithelial hyperplasia in a NHP toxicology study with an alkyne-based mGlu5 NAM developed by Wyeth. This toxicity was believed to be linked to the reactivity of the alkyne based on metabolic studies that revealed extensive glutathione conjugation. While this type of biotransformation does not always manifest in humans with alkyne-containing compounds, many research groups have sought to design novel mGlu5 NAMs that are outside of this chemotype. We have actively pursued a variety of approaches toward that end over the past decade. For example, we conducted a high-throughput screen (HTS) of a collection of 160,000 compounds that identified multiple distinct mGlu5 NAM hits. This same platform functions as our primary assay for lead optimization by measuring the ability of novel compounds to block the mobilization of calcium induced by an EC50 concentration of glutamate in HEK293A cells that express rat mGlu5.

## RESULTS AND DISCUSSION

### Initial Analogs

Recently, we described the discovery of an in vivo tool compound 9 (VU0409106) that resulted from the optimization of one of these HTS hits (Table 1). That report focused exclusively on compounds with a benzamide core; however, we were also interested in exploring picolinamide analogs as well (10–13, Table 1). Moving from the 3-fluorophenyl benzamide core 9 to an unsubstituted picolinamide core (10) reduced potency by approximately 8-fold; however, substitution of the picolinamide core at the 6-position with a methyl group (11) improved potency. In addition, structure–activity relationships (SARs) established in the benzamide series translated to the picolinamides in the form of enhanced potency with the 5-fluoropyridin-3-yl ether (12). Once again, 6-methyl substitution of the picolinamide core (13) improved potency relative to the unsubstituted analog 12. Buoyed by the encouraging results from this limited set of analogs and in search of a compound that represented a step forward from 9 to a compound worthy of advancement to clinical development, we devised a plan to prepare additional 6-

![Figure 1. Prototypical mGlu5 NAM preclinical tools 1 and 2 and clinically investigated mGlu5 NAMs 3–8.](image)

### Table 1. Initial Picolinamide Core Analogs of 9

| no. | mGlu5 IC50 (±SEM) (nM) | mGlu5 IC50 (nM) | % Glu max (%) |
|-----|------------------------|-----------------|--------------|
| 9   | 7.62 ± 0.03            | 24              | 1.2 ± 0.1    |
| 10  | 6.70 ± 0.15            | 200             | 1.2 ± 0.1    |
| 11  | 7.01 ± 0.09            | 98              | 1.3 ± 0.1    |
| 12  | 7.22 ± 0.23            | 60              | 1.4 ± 0.1    |
| 13  | 8.01 ± 0.16            | 10              | 1.3 ± 0.1    |

aCalcium mobilization mGlu5 assay; values are an average of n ≥ 3 independent experiments. bAmplitude of response in the presence of 30 μM test compound as a percentage of maximal response (100 μM glutamate); an average of n ≥ 3 independent experiments.
alkyl-picolinamide analogs. Herein, we report the successful execution of that strategy.

**Synthesis of Compounds.** The synthetic routes to the picolinamide analogs largely mirror those described for the benzamide mGlu5 NAMs. Briefly, 4-nitropyridine-N-oxides were refluxed in concentrated hydrochloric acid to afford 4-chloropyridine-N-oxides (Scheme 1). Alternatively, 4-

![Scheme 1. Synthesis of Picolinamide Analogs 10–13 and 21–37]

“Reagents and conditions: R1 = H, Me, CF3; R2 = H, Me, C6H5; A = N, CH, CF, CCl; R3 = 4-methylthiazol-2-yl or substituted pyridin-2-yl; (a) conc. HCl, reflux, 53–75%; (b) H2O2-urea, (F,S)-COO-O, THF, 0 °C to rt, 44–99%; (c) Me2SiCN, CH2Cl2, Me6NCOCI, 75–86%; (d) K2CO3, DMF, 80 °C, 45–77%; (e) N2aq. NaOH, dioxane, reflux, 82–99%; (f) H2NR4, POCl3, pyridine, −15 °C, 22–81%.

chloropyridines were oxidized with a hydrogen peroxide-urea adduct in the presence of trifluoroacetic acid to provide 16. Treatment of 16 with trimethylsilyl cyanide and dimethylcarbamyl chloride generated 2-cyanopyridines 17. A nucloephic aromatic substitution reaction between heteroaryl alcohols 18 and 17 was employed to generate ether products 19. Hydrolysis of the nitrile moieties of 19 was accomplished via thermal heating with aqueous sodium hydroxide solution to give the penultimate intermediate acids 20. Coupling with the appropriate primary heteroaryl amines (H2NR4) generated the target analogs.

**Initial SAR.** Even though compound 9 is a useful tool for acute behavioral studies in mice and rats, it has several properties that prevent its further development. In particular, 9 has moderate to high clearance in rats (ClR 43 mL/min/kg) and cynomolgus monkeys (ClR 24 mL/min/kg). In addition, 9 has poor bioavailability following oral administration in rats (F < 5%) and is an inhibitor of CYP1A2 (IC50 < 100 nM). Evaluation of the picolinamide analogs of 9 indicated that the 4-methylthiazol-2-yl amide contributed substantially to the potent inhibition of CYP1A2 (e.g., 10 CYP1A2 IC50 < 100 nM), and SAR for mGlu5 activity within the benzamide series showed limited tolerance for even subtle modifications on the thiazol-2-yl moiety. Fortunately, analogs with a pyridin-2-yl replacement of the thiazol-2-yl ring appeared even amenable to substitution, and initial work in the picolinamide series was carried out in that context while taking advantage of SAR knowledge gained from the benzamide work (Table 2).

As expected, the majority of these pyridin-2-yl analogs (21–32) proved to be potent antagonists of mGlu5 on par with their thiazol-2-yl analogs (11 and 13). In a majority of instances, analogs with the 5-fluoropyridin-3-yl ether exhibited slightly superior mGlu5 potency compared to the pyrimidin-5-yl ether analogs; however, the 6-ethylpyridin-2-yl analogs 23 and 24 and 5-chloropyridin-2-yl derivatives 29 and 30 were an exception to this trend. Assays that measured the degree of binding to rat and human plasma and a human liver microsomes (HLM) cocktail assay with probe substrates for four common P450s were used to profile several selected compounds. SAR with regard to the heteroaryl ether group was clear, as the pyrimidin-5-yl ether (Series A) analogs were consistently less bound to plasma than their 5-fluoropyridin-3-yl ether (Series B) analogs. No activity at 30 μM test compound was noted with regard to inhibition of CYP2D6, and inhibition of CYP3A4 and CYP2C9 ranged considerably. As anticipated, the most consistently potent P450 inhibition was observed with CYP1A2; however, there was another clear SAR with respect to the heteroaryl ether group. In this case, the pyrimidin-5-yl ether (Series A) analogs were less potent CYP1A2 inhibitors than the 5-fluoropyridin-3-yl ether (Series B) analogs.

Moving our attention to other portions of the chemotype, we prepared further analogs that revealed additional SAR. Modifications made in the context of the 5-fluoropyridin-2-yl amide found in analogs 27 and 28 are depicted here (Table 3). Installation of a methyl group at the 2-position of the pyrimidin-5-yl ether (33) resulted in a 3-fold loss in potency relative to 27. While this modification increased the extent of binding to plasma, it also reduced inhibition versus CYP1A2 and CYP2C9. Moving to a larger cyclopropyl group at the 2-position of the pyrimidin-5-yl ether (34) substantially eroded potency at mGlu5, indicating minimal tolerance for steric bulk at this position. Likewise, replacement of the 6-methyl group on the picolinamide core with a difluoromethyl group (35) led to an approximately 5-fold loss in mGlu5 potency, illustrating little tolerance for modification at that position. Replacement of the 5-fluoro group of the pyrimidin-3-yl of 28 with a 5-chloro group (36) resulted in only a slight drop in potency. Replacement of the meta-halogen atoms found in 28 and 36 with the para-methyl group in 6-methylpyridin-3-yl ether 37 reduced mGlu5 potency by 50- and 20-fold, respectively.

**In Vivo Pharmacokinetics (PK) Studies.** Previous studies in our laboratories with pyrimidin-5-yl ethers identified this ring as a substrate for aldehyde oxidase (AO)-mediated metabolism. Thus, given the likelihood that several of our interesting new compounds would be subject to non-P450-mediated metabolism, we decided to move directly into an in vivo setting to evaluate the clearance of a variety of select analogs (Table 4). In these studies, the three analogs with the 5-fluoropyridin-2-yl amide group (27, 28, and 33) exhibited superior profiles compared to the other compounds that contained pyridin-2-yl amides with 6-alkyl (21–23) or 6-fluoro (26) groups. The plasma clearance of 26 was greater than hepatic blood flow, which suggests that the instability previously observed in rat plasma for this compound (Table 2) is not merely an in vitro phenomenon. Blocking the 2-position of pyrimidin-5-yl ether (33) reduced clearance and lengthened mean residence time relative to unsubstituted analog 27. Such a result points toward this position as one potential site for metabolism, which is consistent with prior studies on related analog 9,36 Compounds 27, 28, and 33 provided further insight into the SAR of this new chemotype.
were subsequently evaluated in tissue distribution studies (Table 5) using oral dosing. Acceptable CNS penetration was achieved with all three compounds, and unbound brain to unbound plasma ratios ($K_{puu}$) were near unity with 27 and 28, indicating distribution equilibrium between the compartments and a low probability of these two compounds being substrates for transporters in rats.\(^a\) The $K_{puu}$ observed for 33 raises the possibility of active transport with this compound; however, additional studies would be required to conclusively determine if that was indeed the case. All compounds achieved unbound brain levels in excess of their respective mGlu5 functional potency at the dose used in these experiments (10 mg/kg).

Table 2. Substituted 2-Pyridyl Amine Analogs

| no. | series | R   | mGlu5 pIC\(_{50}\) (±SEM)\(^b\) | mGlu5 IC\(_{50}\) (nM)\(^a\) | % Glu max\(^{a,b}\) | protein binding ($f_u$)\(^c\) | P450 inhibition IC\(_{50}\) (μM)\(^d\) |
|-----|--------|-----|--------------------------------|--------------------------|------------------|---------------------|----------------------------|
| 21  | A      | 6-Me| 7.70 ± 0.04                    | 20                       | 1.4 ± 0.1        | 0.076               | 0.066                    |
| 22  | B      | 6-Me| 8.04 ± 0.12                    | 9.1                      | 1.4 ± 0.1        | 0.028               | 0.016                    |
| 23  | A      | 6-Et| 8.03 ± 0.07                    | 9.3                      | 1.5 ± 0.2        | 0.027               | 0.034                    |
| 24  | B      | 6-Et| 7.49 ± 0.31                    | 32                       | 1.2 ± 0.1        | 0.010               | 0.005                    |
| 25  | A      | 6-F  | 7.94 ± 0.21                    | 11                       | 1.3 ± 0.1        | ND\(^e\)            | 0.132                    |
| 26  | B      | 6-F  | 8.45 ± 0.11                    | 3.6                      | 1.4 ± 0.1        | ND\(^e\)            | 0.023                    |
| 27  | A      | 5-F  | 7.97 ± 0.05                    | 11                       | 1.6 ± 0.1        | 0.106               | 0.120                    |
| 28  | B      | 5-F  | 8.51 ± 0.04                    | 3.1                      | 1.2 ± 0.1        | 0.015               | 0.011                    |
| 29  | A      | 5-Cl | 8.17 ± 0.14                    | 6.8                      | 1.3 ± 0.1        | 0.067               | 0.049                    |
| 30  | B      | 5-Cl | 8.02 ± 0.16                    | 9.6                      | 1.3 ± 0.1        | 2.0                 | >30                      |
| 31  | A      | 4-F  | 7.27 ± 0.22                    | 54                       | 1.6 ± 0.3        | >30                 | >30                      |
| 32  | B      | 4-F  | 7.72 ± 0.13                    | 19                       | 1.3 ± 0.2        | 27.4               | >30                      |

\(^{a}\)Calcium mobilization mGlu5 assay; values are an average of $n \geq 3$ independent experiments.\(^{b}\)Amplitude of response in the presence of 30 μM test compound as a percentage of maximal response (100 μM glutamate); an average of $n \geq 3$ independent experiments. \(^{c}\)f\(_u\) = fraction unbound; equilibrium dialysis assay. \(^{d}\)Assayed in pooled HLM in the presence of NADPH with CYP-specific probe substrates. \(^{e}\)Compound was unstable in rat plasma.

Table 3. Analogs of Compound 27 and 28

| no. | series | R   | mGlu5 pIC\(_{50}\) (±SEM)\(^b\) | mGlu5 IC\(_{50}\) (nM)\(^a\) | % Glu max\(^{a,b}\) | protein binding ($f_u$)\(^c\) | P450 inhibition IC\(_{50}\) (μM)\(^d\) |
|-----|--------|-----|--------------------------------|--------------------------|------------------|---------------------|----------------------------|
| 27  | A      | 6-Me| 7.97 ± 0.05                    | 11                       | 1.6 ± 0.1        | 0.106               | 0.120                    |
| 33  | B      | 6-Me| 7.48 ± 0.04                    | 33                       | 1.5 ± 0.2        | 0.081               | 0.074                    |
| 34  | B      | 6-Et| 6.60 ± 0.25                    | 251                      | 1.5 ± 0.1        | 0.015               | 0.011                    |
| 35  | B      | 6-Et| 7.32 ± 0.02                    | 48                       | 1.3 ± 0.1        | 0.058               | 0.014                    |
| 28  | B      | 6-F  | 8.51 ± 0.04                    | 3.1                      | 1.2 ± 0.1        | 4.3                 | >30                      |
| 36  | B      | 6-F  | 8.14 ± 0.27                    | 7.2                      | 1.0 ± 0.1        | 3.8                 | >30                      |
| 37  | B      | 6-F  | 6.80 ± 0.11                    | 158                      | 1.2 ± 0.1        | 21.5               | 0.2                      |

\(^{a}\)Calcium mobilization mGlu5 assay; values are an average of $n \geq 3$ independent experiments.\(^{b}\)Amplitude of response in the presence of 30 μM test compound as a percentage of maximal response (100 μM glutamate); an average of $n \geq 3$ independent experiments. \(^{c}\)f\(_u\) = fraction unbound; equilibrium dialysis assay. \(^{d}\)Assayed in pooled HLM in the presence of NADPH with CYP-specific probe substrates.
perspective, reaching unbound brain levels of 18- and 10-fold over their functional potency, respectively.

Considering their favorable properties, compounds 27 and 28 were selected for oral pharmacokinetic and bioavailability studies in rats and cynomolgus monkeys (Table 6). Cynomolgus monkeys were chosen as a second preclinical species as it has been established that AO activity varies across species. Specifically, AO activity is highest in humans and NHPs, moderate in rats, and undetectable in dogs. Using in vitro methods described previously for 9,38,40 we confirmed that AO contributed significantly to the metabolism of 27 in rats, cynomolgus monkey, and human hepatic S9 fractions (Figure 2). Oral exposure was significant as bioavailability exceeded 50% with both compounds in rats. Compound 27 exhibited an earlier and slightly higher plasma Cmax than 28; however, the lower clearance of 27 resulted in prolonged exposure and larger area under the curve (AUC) than observed for 27. The PK results from analogous studies in cynomolgus monkeys showed these compounds to be similar in that both compounds showed a clearance of approximately one-third of hepatic blood flow. Bioavailability, while lower than that observed in rats, was still >30% in each case. With largely attractive in vivo PK profiles, both compounds were advanced into further studies to identify additional factors for differentiation.

Ancillary Pharmacology. To judge the selectivity of these analogs versus the other members of the mGlu receptor family, the effects of both 27 and 28 at 10 μM on the orthosteric agonist concentration response curve (CRC) were measured in fold-shift experiments.45,46 No significant effects on the agonist CRC were noted with either compound, indicating excellent selectivity for mGlu5. To assess potential ancillary pharmacology, both compounds were screened at 10 μM in a commercial radioligand binding assay panel of 68 diverse and clinically relevant targets (see Supporting Information).47 While 27 had no significant responses at any target, where significant responses are defined as inhibition of more than 50% of radioligand binding, one significant response of 86% inhibition was noted for 28 at the dopamine transporter (DAT). For comparison, 27 only inhibited DAT at a level of 34%. A subsequent CRC was obtained, and 28 was found to inhibit radioligand binding with an IC50 of 1.54 μM. Since inhibition of DAT is associated with abuse potential,48 we next evaluated 28 in a functional cell-based assay that measured inhibition of dopamine uptake.49 Indeed, consistent with results obtained from the binding assay, 28 exhibited an IC50 of 1.38 μM in this assay. While 28 is more than 400-fold selective for mGlu5 versus DAT, the lack of concern regarding this target in the case of 27 was viewed as a positive for that compound. With its preferable P450 inhibition profile (Table 2) and the higher unbound brain concentrations achieved in rats also in its favor, the decision was made to proceed with additional detailed characterization of 27.

Detailed Characterization of 27. Having narrowed our interest to analog 27, we carried out a more thorough characterization of its interaction with mGlu5 (Figure 3). First, to ensure that there was no appreciable species difference in the mGlu5 activity of 27, we carried out our calcium mobilization assay in HEK293A cells expressing the human receptor (Figure 3A). As anticipated, the potency difference between rat (IC50 = 11 nM) and human mGlu5 (IC50 = 14 nM) was negligible. To study the effects of 27 on mGlu5 activity in a native system, experiments in rat cortical astrocytes were conducted (Figure 3B). As expected, 27 induced a concentration-dependent rightward shift of the glutamate CRC and decreased the maximal response to glutamate. To investigate whether 27 interacted with the mGlu5 allosteric site that is common to many mGlu5 NAMs such as 1 and 2 (Figure 1), we also carried out a competition radioligand binding assay with [3H]-3-methoxy-5-(pyridin-2-ylethynyl)pyridine (39)50 (Figure 3C) in membranes prepared from HEK293A cells expressing rat mGlu5. This study confirmed the interaction of 27 with this known binding site (mGlu5, IC50 = 4.4 nM). We also performed saturation binding experiments with increasing concentrations of [3H]-38 in the presence and absence of multiple concentrations of 27 (Figure 3D,E). Increasing concentrations of 27 had no effect on the Bmax of the radioligand but increased the KD as shown (Figure 3D), a finding that suggests a competitive interaction between 27 and [3H]-39. Scatchard analysis (Figure 3E) of the results plotting bound/free versus

### Table 5. Tissue Distribution Studies Using Oral Dosing

| no. | mGlu5 IC50 (nM) | protein binding (fub) | total plasma | total brain | unbound plasma | unbound brain | Kp | Kpmax | unbound brain/mGlu5 IC50 |
|-----|----------------|-----------------------|--------------|------------|---------------|--------------|----|-------|------------------------|
| 27  | 11             | 0.106 0.078           | 3000         | 2580       | 318           | 201          | 0.86| 0.63  | 18                     |
| 28  | 3.1            | 0.015 0.111           | 2570         | 2870       | 38.6          | 31.1         | 1.1 | 0.82  | 10                     |
| 33  | 33             | 0.081 0.044           | 4820         | 3220       | 390           | 142          | 0.67| 0.36  | 4.3                    |

**Note:** Average n = 2, male Sprague–Dawley rats; dose = 10 mg/kg; vehicle = 10% polysorbate in 80% methylene chloride; t = 1 h post-dose. Calcium mobilization mGlu5 assay; values are an average of ≥ 3 independent experiments. fub = Fraction unbound; equilibrium dialysis assay; brain = mouse brain homogenates. Kp = total brain to total plasma ratio. Kpmax = unbound brain (brain fub × total brain) to unbound plasma (plasma fub × total plasma) ratio.
bound ligand demonstrated that addition of 27 induced a change in slope of the regression line (change in $K_d$) but had no effect on the $x$-intercept (no change in $B_{max}$). These data are consistent with 27 competitively displacing $[^3H]$-39 at the aforementioned known allosteric binding site. A final set of radioligand kinetic binding experiments was conducted that examined the effect of 27 on the dissociation of $[^3H]$-38. In these studies, neither concentration (300 nM or 100 nM) of 27 had any effect on the dissociation rate of the radioligand (data not shown), a result consistent with prior studies and a competitive interaction. Lastly, we examined the effects of increasing concentrations of the mGlu5 neutral site ligand 5-methyl-6-(phenylethynyl)-pyridine (40) on the calcium mobilization CRC of 27 in HEK293A cells expressing rat mGlu5 (Figure 3F). In these experiments, 40 induced a parallel rightward shift in the 27 concentration response relationship, which is consistent with 40 competing for the known allosteric binding site with 27. Furthermore, a Schild analysis (data not shown) of the effects of 40 on the 27 concentration response yielded a linear regression with a slope of 0.96, indicating the relationship between the two compounds was competitive. Extrapolation of the line to the $x$-intercept established a $K_i$ of approximately 240 nM, a result consistent with the $K_i$ value for 40 at the $[^3H]$-39 site as described in the literature (388 nM). Each of these studies combine to conclusively establish that 27 binds in a competitive manner to the aforementioned known mGlu5 allosteric binding site.

With a detailed understanding of the pharmacology of 27 in hand, we moved the compound into a host of additional assays designed to identify potential risks for clinical development (Table 7). Permeability and potential for P-glycoprotein (P-gp)-mediated efflux was assessed in both Madin–Darby canine kidney (MDCK) cells transfected with the human MDR1 gene and human colon carcinoma derived Caco-2 cells. Permeability was moderate, and efflux ratios were near unity in increasing concentrations of the mGlu5 neutral site ligand 5-methyl-6-(phenylethynyl)-pyridine (40). On the calcium mobilization CRC of 27 in HEK293A cells expressing rat mGlu5 (Figure 3F). In these experiments, 40 induced a parallel rightward shift in the 27 concentration response relationship, which is consistent with 40 competing for the known allosteric binding site with 27. Furthermore, a Schild analysis (data not shown) of the effects of 40 on the 27 concentration response yielded a linear regression with a slope of 0.96, indicating the relationship between the two compounds was competitive. Extrapolation of the line to the $x$-intercept established a $K_i$ of approximately 240 nM, a result consistent with the $K_i$ value for 40 at the $[^3H]$-39 site as described in the literature (388 nM). Each of these studies combine to conclusively establish that 27 binds in a competitive manner to the aforementioned known mGlu5 allosteric binding site.

With a detailed understanding of the pharmacology of 27 in hand, we moved the compound into a host of additional assays designed to identify potential risks for clinical development (Table 7). Permeability and potential for P-glycoprotein (P-gp)-mediated efflux was assessed in both Madin–Darby canine kidney (MDCK) cells transfected with the human MDR1 gene and human colon carcinoma derived Caco-2 cells. Permeability was moderate, and efflux ratios were near unity in increasing concentrations of the mGlu5 neutral site ligand 5-methyl-6-(phenylethynyl)-pyridine (40). On the calcium mobilization CRC of 27 in HEK293A cells expressing rat mGlu5 (Figure 3F). In these experiments, 40 induced a parallel rightward shift in the 27 concentration response relationship, which is consistent with 40 competing for the known allosteric binding site with 27. Furthermore, a Schild analysis (data not shown) of the effects of 40 on the 27 concentration response yielded a linear regression with a slope of 0.96, indicating the relationship between the two compounds was competitive. Extrapolation of the line to the $x$-intercept established a $K_i$ of approximately 240 nM, a result consistent with the $K_i$ value for 40 at the $[^3H]$-39 site as described in the literature (388 nM). Each of these studies combine to conclusively establish that 27 binds in a competitive manner to the aforementioned known mGlu5 allosteric binding site.

Table 6. Rat and Cynomolgus Monkey Pharmacokinetics of Compounds 27 and 28

| no. | $t_{1/2}$ (min)$^c$ | MRT (min)$^c$ | $Cl_p$ (mL/min/kg)$^c$ | $V_{SS}$ (L/kg)$^c$ | $T_{max}$ (min)$^d$ | $C_{max}$ (μM)$^d$ | AUC (μM·h)$^d$ | % F$^d$ |
|-----|-------------------|--------------|-------------------|-------------------|-----------------|----------------|---------------|--------|
| 27  | 390               | 93           | 19.3              | 1.8               | 30              | 4.34          | 14.6          | 53     |
| 28  | 281               | 208          | 9.2               | 1.9               | 90              | 3.33          | 38.0          | 71     |

$^a$Oral vehicle = 10% polysorbate 80 in 0.5% methyl cellulose; IV vehicle = 10% EtOH, 70% PEG 400, 20% saline. $^b$Average $n = 2$ male Sprague–Dawley rats. $^c$t$_{1/2}$ = Terminal phase plasma half-life; MRT = mean residence time; $Cl_p$ = plasma clearance; $V_{SS}$ = volume of distribution at steady-state. $^dT_{max} = time at which maximum concentration occurs; C_{max} = maximum concentration; AUC = area under the curve; F = bioavailability. $^e$Average $n = 2$ male cynomolgus monkeys.

Figure 2. Metabolite (38) of 27 identified in rat, cynomolgus monkey, and human hepatic S9 fractions that is produced predominately by AO.
both cell lines, indicating a low potential for transporter-mediated efflux. A definitive and expanded assessment of the ability of 27 to reversibly inhibit the metabolism of isoform-selective probe substrates of P450s was conducted. Results were generally consistent with the preliminary results (Table 2) with moderate inhibition of CYP1A2 observed. In parallel to these studies, the potential for 27 to time-dependently inhibit each P450 was assessed with no evidence of time-dependent inhibition noted in any case. To shed further light on the likely human PK profile of 27, the stability of the compound was assessed in human cryopreserved hepatocytes, a system which is potentially useful for evaluating compounds with non-P450-mediated routes of metabolism such as AO. Gratifyingly, the predicted hepatic clearance in humans using this method was low with a half-life of more than 5 h. To assess any potential cardiac liabilities, 27 was subjected to a commercial ion channel panel. Fortunately, no significant risks were identified in this panel. Finally, the potential mutagenic activity of 27 was investigated in the bacterial reverse mutation assay (Ames assay), and no mutagenic responses were noted in any of the five strains either in the presence or absence of S9 metabolic activation. Encouraged by the overall profile of 27, we advanced this compound to behavioral assays in the rat.

Behavioral Pharmacology. It is well-known that mice will bury foreign objects such as glass marbles in deep bedding. Likewise, pretreatment with low doses of benzodiazepines and multiple mGlu5 NAM tool compounds have been shown to inhibit this behavior. It has been argued recently that the marble burying assay models the repetitive and perseverative behavior associated with OCD as opposed to novelty-induced anxiety. We have also employed this rapid assay that utilizes naïve mice as a frontline behavioral screen for our discovery programs directed toward mGlu5 NAMs. Using intraperitoneal (IP) dosing as a convenient route for rapidly and accurately dosing large numbers of animals, we examined the effects of 27 in this study (Figure 4A). Dose-dependent effects on marble burying were observed, and all doses ≥0.3 mg/kg produced significant effects relative to the vehicle control. The 3.0 mg/kg dose produced an effect on marble burying on par with the positive control 2 (15 mg/kg) in this study. A satellite experiment was conducted using the 3.0 mg/kg dose, and brain samples were collected and analyzed for exposure of 27. At 15 min post-dose of 27, which correlates to the initiation time point of the marble burying study, the total brain concentration of 27 was 1.48 µM. Calculation of the unbound brain concentration using equilibrium dialysis data (Table 5) yields a level of 115 nM, which is approximately 10-fold more than the functional mGlu5 activity. Having observed efficacy in this model of anxiety/OCD, we next studied 27 in an animal model of depression as well. The forced swim test (FST) measures the duration of immobility observed in rats suspended in a tank of water from which they cannot escape. Many clinical antidepressants are able to reduce the time that the animals are immobile while increasing the time that they are active. Furthermore, certain mGlu5 NAMs have also shown efficacy in this model of depression. Examination of 27 in this assay showed a dose-dependent ability of the compound to reduce the duration of immobility indicative of antidepressant activity (Figure 4B). This result compares favorably to the literature report for 7 in the same assay, where that compound had a minimum efficacious dose of 10 mg/kg (PO). The high dose used in this study (30 mg/kg

Figure 3. (A) Ca2+ mobilization assay CRC for 27 in HEK293A cells expressing human mGlu5. (B) Effects of 27 on glutamate CRC in rat cortical astrocytes. (C) Competition radioligand binding CRC with 27 and [3H]-3-methoxy-5-(pyridin-2-ylethynyl)pyridine (39). (D) Saturation binding experiment: increasing concentrations of [3H]-39 in the presence and absence of multiple concentrations of 27. (E) Saturation binding experiment: Scatchard analysis of bound/free versus bound ligand. (F) Effects of the neutral mGlu5 site ligand 5-methyl-6-(phenylethynyl)-pyridine (40) on the functional inhibition of glutamate responses induced by 27.
A report from last year implicated ketamine as the potential source of these rapid antidepressant effects. Interestingly, prior studies have shown that the antidepressant activity in the FST with mGlu5 NAMs involved signaling through the NMDA but not the AMPA receptor. Thus, the mechanisms by which ketamine and mGlu5 NAMs illicit their antidepressant effects may well be distinct.

**Imaging Studies.** Recognizing that an ability to study receptor occupancy (RO) in the clinic would represent a potential advantage for advancing 27, we decided to investigate RO studies in preclinical species. [18F]-3-Fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ([18F]-FPEB, [18F]-41) is a close structural analog of radioligand [3H]-38 that has been used both preclinically and in the clinic as a positron emission tomography (PET) ligand for studying mGlu5 RO. Thus, we decided to carry out [18F]-41 μPET studies with 27 in rats (Figure 5). In these studies, 27 was dosed orally 30 min prior to IV dosing of [18F]-41. PET imaging was initiated and continued for 1 h. Representative images demonstrating dose-dependent displacement of [18F]-41 by 27 are depicted in Figure 5A. Maximum occupancy of 80% was achieved at 10 mg/kg 27 (Figure 5B). Plasma samples were collected throughout the study. Plotting the maximum unbound plasma concentration of 27 versus RO resulted in an unbound level Occ50 of 13 nM (Figure 5C). Plotting the dose of 27 versus the RO normalized to the maximum displacement of [18F]-41 gave an RO50 of 0.8 mg/kg (Figure 5D).

Based on the RO results in rats, we next investigated whether similar results would be obtained in NHPs. As such, we advanced 27 into studies in baboons using the same radiotracer [18F]-41 (Figure 6). The design for this experiment was very similar to the aforementioned study in rats; however, in this case, both 27 and the radiotracer were delivered via IV administration. There was a clear reduction in the uptake of [18F]-41 relative to baseline that followed a dose-dependent relationship with 27 (Figure 6A,D,E). The maximum dose resulted in 89% RO of mGlu5. Plasma samples were again taken throughout the study to analyze 27 levels, and RO was plotted against the plasma maximum to arrive at a total plasma Occ50 of 56 nM (Figure 6B). If one assumes that human and baboon plasma protein binding is similar, then this equates to a plasma unbound Occ50 of 6.7 nM, which is within 2-fold of that observed in the rodent study. The effective IV dose that produces 50% RO (RO50) was determined to be 0.06 mg/kg (Figure 6C).

**Table 7. Further in Vitro Characterization of 27**

| cell line       | Papp (A–B) (cm/s) | Papp (B–A) (cm/s) | efflux ratio |
|-----------------|-------------------|-------------------|-------------|
| MDCK-MDR1       | 6.2 × 10⁻⁶        | 7.2 × 10⁻⁶        | 1.2         |
| Caco-2          | 6.5 × 10⁻⁶        | 7.9 × 10⁻⁶        | 1.2         |

**Figure 4.** (A) Dose-dependent inhibition of marble burying with 27; vehicle = 10% polysorbate 80 (IP); male CD-1 mice; n = 10 per treatment group; 15 min pretreatment; 30 min burying time; *, p < 0.05 versus vehicle control group, Dunnett’s test; bars denote marbles buried. (B) Dose-dependent inhibition of immobility in rats with 27; vehicle = 10% polysorbate 80 (27, intraperitoneal) and sterile saline (ketamine, subcutaneous); male Sprague-Dawley rats; n = 8–10 per treatment group; 30 min pretreatment; 6 min testing session; *, p < 0.05 versus vehicle control group, Dunnett’s test; bars denote duration of immobility in s.

IP) produced an efficacy equivalent to that of the positive control, ketamine, a known antagonist of the N-methyl-D-aspartate (NMDA) receptor. Though ketamine is an older drug and produces undesirable psychotomimetic side effects, more recent clinical studies have shown that it can induce a rapid antidepressant effect in patients with treatment-resistant depression (TRD). A report from last year implicated the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor by a specific ketamine metabolite rather than direct antagonism of the NMDA receptor by ketamine as the potential source of these rapid antidepressant effects.62 Interestingly, prior studies have shown that the antidepressant activity in the FST with mGlu5 NAM 2 involved signaling through the NMDA but not the AMPA receptor. Thus, the mechanisms by which ketamine and mGlu5 NAMs illicit their antidepressant effects may well be distinct.

**Imaging Studies.** Recognizing that an ability to study receptor occupancy (RO) in the clinic would represent a potential advantage for advancing 27, we decided to investigate RO studies in preclinical species. [18F]-3-Fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ([18F]-FPEB, [18F]-41) is a close structural analog of radioligand [3H]-38 that has been used both preclinically and in the clinic as a positron emission tomography (PET) ligand for studying mGlu5 RO. Thus, we decided to carry out [18F]-41 μPET studies with 27 in rats (Figure 5). In these studies, 27 was dosed orally 30 min prior to IV dosing of [18F]-41. PET imaging was initiated and continued for 1 h. Representative images demonstrating dose-dependent displacement of [18F]-41 by 27 are depicted in Figure 5A. Maximum occupancy of 80% was achieved at 10 mg/kg 27 (Figure 5B). Plasma samples were collected throughout the study. Plotting the maximum unbound plasma concentration of 27 versus RO resulted in an unbound level Occ50 of 13 nM (Figure 5C). Plotting the dose of 27 versus the RO normalized to the maximum displacement of [18F]-41 gave an RO50 of 0.8 mg/kg (Figure 5D).

Based on the RO results in rats, we next investigated whether similar results would be obtained in NHPs. As such, we advanced 27 into studies in baboons using the same radiotracer [18F]-41 (Figure 6). The design for this experiment was very similar to the aforementioned study in rats; however, in this case, both 27 and the radiotracer were delivered via IV administration. There was a clear reduction in the uptake of [18F]-41 relative to baseline that followed a dose-dependent relationship with 27 (Figure 6A,D,E). The maximum dose resulted in 89% RO of mGlu5. Plasma samples were again taken throughout the study to analyze 27 levels, and RO was plotted against the plasma maximum to arrive at a total plasma Occ50 of 56 nM (Figure 6B). If one assumes that human and baboon plasma protein binding is similar, then this equates to a plasma unbound Occ50 of 6.7 nM, which is within 2-fold of that observed in the rodent study. The effective IV dose that produces 50% RO (RO50) was determined to be 0.06 mg/kg (Figure 6C).
CONCLUSION

Continuation of our mGlu5 NAM discovery program that began with a cell-based HTS has culminated in the identification of the highly optimized compound 27 (VU0424238).65 Compound 27 is a highly potent and selective antagonist of mGlu5 with a favorable preclinical profile. The molecule has low-moderate clearance and good oral bioavailability in two species. Compound 27 displays CNS penetration in rodents, and we believe that the compound is a low risk for transporter-mediated efflux and drug–drug interactions. While the compound is a moderate inhibitor of CYP1A2, this aspect is considered manageable. Importantly, the compound is active in preclinical models of anxiety/OCD and depression, both of

Figure 5. Imaging studies in rodents; n = 4–8 Sprague–Dawley rats; 27 vehicle = 10% polysorbate 80 in 0.5% methyl cellulose; 27 dosed 30 min prior to [18F]-41 (IV). (A) Representative images of [18F]-41 by increasing oral doses of 27. (B) mGlu5 RO obtained with [18F]-41 and increasing oral doses of 27. (C) Unbound maximum plasma concentration of 27 versus mGlu5 RO. (D) Dose of 27 versus mGlu5 RO; *normalized to the maximum displacement of [18F]-41.

Figure 6. Imaging studies in female baboons: subject A received three doses (0.01, 0.1, and 0.18 mg/kg); subject B received two doses (0.03 and 0.56 mg/kg); 27 vehicle = 10% ethanol, 30% PEG 400, 20% hydroxypropyl-β-cyclodextrin in water; 27 dosed over 20 min, 30 min prior to [18F]-41 (IV, 3 min bolus) for all doses except the 0.18 mg/kg dose, which was dosed over 2 min, 50 min prior to [18F]-41. (A) mGlu5 RO obtained in two female baboons with [18F]-41 and increasing IV doses of 27. (B) Total maximum plasma concentration of 27 versus mGlu5 RO. (C) Dose of 27 versus mGlu5 RO. (D) Images for subject A averaged from 0 to 150 min. (E) Images for subject B averaged from 0 to 180 min.
which are assays where mGlu, NAMs have shown activity in the past. Moreover, a clinically useful radiotracers has been used to demonstrate mGlu, RO by 27 in both rodent and NHPs. Based on the totality of data, we have selected 27 for advancement to clinical development including studies designed to enable an investigational new drug (IND) application. Here is the public disclosure of the chemical structure of 27, our candidate for clinical studies. Future publications describing detailed metabolic profiling, chemical process development and formulation, and toxicology studies are under preparation and will be communicated in the near future.

**EXPERIMENTAL SECTION**

**Synthetic Procedures and Characterization Data. General.** All NMR spectra were recorded on a 400 MHz AMX Bruker NMR spectrometer. 1H and 13C chemical shifts are reported in δ values in ppm downfield from the deuterated solvent as the internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, b = broad, m = multiplet), integration, coupling constant (Hz). High-resolution mass spectra were obtained on an Agilent 6540 UHD Q-TOF with ESI source. MS parameters were as follows: fragmentor: 150, capillary voltage: 3500 V, nebulizer pressure of 40 psi. The capillary needle voltage was 3000 V, flow was 11 L/min at a temperature of 350 °C and a nebulizer pressure of 40 psi. The capillary needle voltage was 3000 V, and the fragmentor voltage was 70 V.

**Preparation of Compound 27. 4-Chloro-2-methylpyridine-N-oxide (16a).** 2-methyl-4-nitropyridine 1-oxide 14a (5.0 g, 32 mmol, 1.0 equiv) was dissolved in concentrated HCl (80 mL) and refluxed for 3 days. The reaction was cooled, and the excess concentrated HCl was removed in vacuo. The viscous oil was neutralized with 10% K2CO3 and extracted with CH2Cl2 (5x). The combined organs were dried (MgSO4), filtered, and concentrated in vacuo. Purification by flash chromatography on silica gel afforded 3.49 g (75%) of the title compound as a yellow solid.

**Alternative Procedure: 4-Chloro-2-methylpyridine 15a (5.0 g, 39 mmol, 1.0 equiv) and hydrogen peroxide-urea adduct (7.37 g, 78.4 mmol, 2.0 equiv) were dissolved in THF (196 mL) and cooled to 0 °C. Trifluoroacetic anhydride (12 mL, 86.3 mmol, 2.2 equiv) was added dropwise over 15 min, and the reaction was allowed to warm to room temperature. After determination of the completion of the reaction by LCMS (approximately 45 min), the reaction was cooled to 0 °C and quenched with a 10% aqueous solution of sodium thiosulfate.

The reaction was extracted with EtOAc (3x), dried (MgSO4), filtered, and concentrated in vacuo. Purification by flash chromatography on silica gel afforded 5.63 g (99%) of the title compound as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.23 (d, J = 7.0 Hz, 1H), 7.66 (d, J = 3.0 Hz, 1H), 7.40 (dd, d = 7.0, 3.0 Hz, 1H), 2.32 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 149.53, 139.78, 128.73, 126.41, 124.17, 17.09 ppm; LCMS (Method 1): Rf = 0.302 min, m/z = 144.2 [M + H]+; HRMS, calcd for C7H6NO [M], 143.0138; found 143.0139.

**6-Methyl-4-((pyrimidin-5-yloxy)picolinonitrile (17a).** Compound 16a (8.97 g, 62.5 mmol, 1.0 equiv) was dissolved in CH2Cl2 and dried over MgSO4. The solution was added to a flame-dried round-bottom flask, and CH2Cl2 was added to give a total volume of 188 mL. Trimethylsilyl cyanide (10 mL, 75 mmol, 1.2 equiv) was added, and the reaction stirred for 15 min. Dimethylcarbamyl chloride (6.9 mL 75 mmol, 1.2 equiv) was added dropwise over 20 min, and the reaction was stirred for 24 h. An additional 1 equiv each of trimethylsilylcyanide and dimethylcarbamyl chloride were added, and the reaction was stirred for another 72 h. The reaction was made basic with 10% K2CO3, and extracted with CH2Cl2 (3x). The combined organs were dried (MgSO4), filtered, and concentrated in vacuo. Puriﬁcation by flash chromatography on silica gel afforded 7.2 g (76%) of the title compound as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.13 (d, J = 1.6 Hz, 1H), 7.82 (d, J = 1.7 Hz, 1H), 2.52 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ = 161.99, 144.13, 133.01, 127.65, 126.40, 116.60, 23.57 ppm; LCMS (Method 1): Rf = 0.715 min, m/z = 153.2 [M + H]+; HRMS, calcd for C6H6ClNO [M], 152.0144; found 152.0139.

**6-Methyl-4-((pyrimidin-5-yloxy)pyrrolinol (19a).** Compound 17a (4.0 g, 26 mmol, 1.0 equiv), 5-hydroxypyrindine 18a (5.56 g, 57.9 mmol, 2.2 equiv), K2CO3 (7.24 mg, 52.4 mmol, 2.0 equiv), and DMF (66 mL) were added to a reaction vessel and heated at 80 °C for 16 h. The reaction was cooled, and the excess concentrated HCl was neutralized with NaHCO3, the reaction was dissolved in 10% MeOH/CH2Cl2. The undissolved salt was filtered, and concentrated in vacuo. Puriﬁcation by flash chromatography on silica gel afforded 4.65 g (77%) of the title compound as a pale-yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 9.17 (s, 1H), 8.85 (s, 2H), 7.74 (d, J = 2.4 Hz, 1H), 7.32 (d, J = 2.3 Hz, 1H), 2.48 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ = 164.04, 162.28, 155.51, 150.02, 148.75, 133.54, 117.05, 115.95, 114.05, 23.82 ppm; LCMS (Method 1): Rf = 0.535 min, m/z = 213.2 [M + H]+; HRMS, calcd for C6H5N5O2 [M], 212.0698; found 212.0697.

**6-Methyl-4-((pyrimidin-5-yloxy)pyrrolinilic acid (20a).** Compound 19a (4.31 g, 20.3 mmol, 1.0 equiv) was dissolved in dioxane (90 mL), and 2 N NaOH (45 mL) was added. The mixture was refluxed for 18 h, and after cooling, the reaction was neutralized with 2 N HCl (45 mL). The water and solvent were removed in vacuo, and the crude reaction was dissolved in 10% MeOH/CH3Cl. The undissolved salt was ﬁltered off, and the solvents were removed in vacuo to afford 4.65 g (99%) of the title compound as a white solid which was used without further puriﬁcation.

 Compound 20a (16.84 g, 72.83 mmol, 1.0 equiv) and 5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)pyrrolinilide (27). Compound 20a (16.84 g, 72.83 mmol, 1.0 equiv) and 5-fluoropyridin-2-yl) were
dissolved in pyridine (485 mL) in a flame-dried round-bottom flask. The reaction was cooled to −15 °C, and phosphorus oxychloride (7.47 mL, 80.14 mmol, 1.1 equiv) was added dropwise while keeping the temperature below −15 °C. After stirring for 30 min at −15 °C, the reaction was quenched with ice–water and neutralized with 10% K₂CO₃. The mixture was extracted with EtOAc (3×), and the combined organics were dried (MgSO₄), filtered, and concentrated in vacuo. Purification by flash chromatography on silica gel afforded 14.3 g (60%) of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.48 (s, 1H), 9.18 (s, 1H), 8.88 (s, 2H), 8.60 (d, J = 3.0 Hz, 1H), 8.27 (dd, J = 9.2 Hz, 4.10 Hz, 1H), 7.86 (td, J = 8.6, 3.1 Hz, 1H), 7.55 (d, J = 2.3 Hz, 1H), 7.29 (d, J = 2.3 Hz, 1H), 2.58 (s, 3H); ¹³C NMR (100 MHz, DMSO-d₆) δ 165.15, 161.11, 160.57, 156.12 (d, J(C,F) = 25.5 Hz), 125.83 (d, J(C,F) = 19.9 Hz), 114.56, 114.27 (d, J(C,F) = 4.7 Hz), 108.01, 23.84 ppm; LCMS (Method 2): Rᵣ = 0.727 min, m/z = 326.2 [M + H]⁺; HRMS, calc'd for C₁₆H₁₂FN₅O₂ [M⁺]: 325.0975; found 325.0979.

N-(4-Methylthiazol-2-yl)-4-(pyrimidin-5-yl)picolinamide (10). Prepared analogous to compound 27. LCMS (Method 3): Rᵣ = 1.147 min, m/z = 314.2 [M + H]⁺.

6-Methyl-N-(4-methylthiazol-2-yl)-4-(pyrimidin-5-yl)picolinamide (11). Prepared analogous to compound 27. LCMS (Method 2): Rᵣ = 0.670 min, m/z = 328.2 [M + H]⁺.

4-((5-Fluoropyridin-3-yl)oxy)-6-methyl-N(5-fluoromethyl)-N-(5-fluoropyridin-2-yl)-4-((6-methylpyridin-3-yl)oxy)picolinamide (35). Prepared analogous to compound 27. LCMS (Method 2): Rᵣ = 0.765 min, m/z = 362.1 [M + H]⁺.

4-((5-Chloropyridin-3-yl)oxy)-N-(5-fluoropyridin-2-yl)-6-methylpicolinamide (36). Prepared analogous to compound 27. LCMS (Method 1): Rᵣ = 0.942 min, m/z = 359.1 [M + H]⁺.

N-(5-Fluoropyridin-2-yl)-6-methyl-4-((6-methylpyridin-3-yl)oxy)picolinamide (37). Prepared analogous to compound 27. LCMS (Method 1): Rᵣ = 0.639 min, m/z = 339.1 [M + H]⁺.

**ASSOCIATED CONTENT**

**Supporting Information**

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.7b00410.

Molecular pharmacology methods, complete ancillary pharmacology profile details for 27 and 28, drug metabolism and pharmacokinetic (DMPK) methods, behavioral pharmacology methods, and in vivo occupancy methods (PDF)

Molecular formula strings (CSV)

**AUTHOR INFORMATION**

**Corresponding Author**

E-mail: kyle.emmitte@unthsc.edu. Phone: 817-735-2041. Fax: 817-735-2603.

**ORCID**

Craig W. Lindsley: 0000-0003-0168-1445 Kyle A. Emmitte: 0000-0002-6643-3947

**Present Address**

Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, Texas 76107, United States.

**Author Contributions**

K.A.E. and C.W.L. directed and designed the chemistry. A.S.F. and B.S.B. performed the medicinal chemistry. P.J.C. and K.A.E. and C.W.L. directed and designed the chemistry. A.L.B. directed and designed the molecular pharmacology methods, complete ancillary pharmacology methods, and in vivo occupancy methods. D.F.V. and V.B.L. performed molecular pharmacology experiments. J.S.D. directed and designed the DMPK experiments. A.L.B. directed and designed DMPK experiments and performed bioanalytical work. R.D.M. performed bioanalytical work. S.C. performed in vitro DMPK experiments and performed bioanalytical work. R.D.M. performed bioanalytical work. S.C. performed in vitro DMPK experiments. F.W.B. performed in vivo DMPK work. C.K.J. directed, designed, and performed behavioral experiments. A.T.G. performed behavioral experiments. J.M.R. designed and performed the rat brain occupancy experiments. M.N.T. performed rat brain occupancy experiments. G.D.T. was the study director for the NHP brain occupancy study.

**Notes**

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

We gratefully acknowledge the generous support of the National Institute of Mental Health (U19 MH097056-01) (P.J.C.), the National Institute on Drug Abuse (R01 DA023947-01) (C.W.L.), Seaside Therapeutics (VUMC33842), and The William K. Warren Foundation for their support of our programs focused on the development of mGlu₅ NAMs.
AD, Alzheimer’s disease; AMU, atomic mass units; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolopropionic acid; AO, aldehyde oxidase; ASD, autism spectrum disorder; AUC, area under the curve; Bmax, maximum amount of radioligand which can bind specifically to the receptors in a membrane preparation; Cmax, maximum concentration; CLHEP, predicted hepatic clearance; CLint, intrinsic clearance; CLp, plasma clearance; CNS, central nervous system; CRC, concentration response curve; DAT, dopamine transporter; DMF, N,N-dimethylformamide; DMPK, drug metabolism and pharmacokinetics; IC50, the concentration of agonist that affords a half-maximal response; Et, ethyl; EtOAc, ethyl acetate; FPEB, 3-fluoro-5-[(pyridin-3-yl)ethynyl][benzonitrile; FST, forced swim test; F, bioavailability; fub, fraction unbound; FXS, fragile X syndrome; Glu, glutamate; GPCR, G-protein-coupled receptors; h, hours; HEK, human embryonic kidney; HLM, human liver microsomes; HTS, high-throughput screen; IC50, the concentration of antagonist at which 50% of receptor function is inhibited; IND, investigational new drug; IP, intraperitoneal; IV, intravenous; Kd, the concentration of compound that will bind half of the binding sites at equilibrium; Kp, brain to plasma ratio; Kp,unbound brain to unbound plasma ratio; L, liters; LID, levodopa-induced dyskinesia; MDCK, Madin–Darby canine kidney; MDD, major depressive disorder; Me, methyl; mGlu, metabotropic glutamate receptor; MPEP, methyl-6-(phenethyl)pyridine; min, minutes; MRT, mean residence time; MTEP, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine; NADPH, nicotinamide adenine dinucleotide phosphate (reduced form); NAM, negative allosteric modulator; NMDA, N-methyl-D-aspartate; NHP, nonhuman primate; Occ, concentration of drug that produces 50% receptor brain occupancy; OCD, obsessive-compulsive disorder; PAM, positive allosteric modulator; PD, Parkinson’s disease; PEG, polyethylene glycol; PET, positron emission tomography; P-gp, P-glycoprotein; PK, pharmacokinetics; RO, receptor occupancy; RO,unbound dose of compound that results in 50% receptor occupancy; s, seconds; SAR, structure–activity relationship; SEM, standard error of the mean; THF, tetrahydrofuran; TRD, treatment-resistant depression; T1/2, half-time at which maximum concentration of test compound occurs; t1/2, half-life; VSS, volume of distribution at steady-state; VFT, venus fly trap; 7TM, seven transmembrane.

REFERENCES

(1) Golubeva, A. V.; Moloney, R. D.; O’Connor, R. M.; Dinan, T. G.; Cryan, J. F. Metabotropic glutamate receptors in central nervous system disease. Curr. Drug Targets 2016, 17, 538–616.
(2) Gregory, K. J.; Noetzel, M. J.; Rook, J. M.; Vinson, P. N.; Stauffer, S. R.; Rodriguez, A. L.; Emmette, K. A.; Zhou, Y.; Chua, A. C.; Felts, A. S.; Chauder, B. A.; Lindsley, C. W.; Niswender, C. M.; Conn, P. J. Investigating validated metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Mol. Pharmacol. 2012, 82, 860–875.
(3) Lindsley, C. W.; Emmette, K. A.; Hopkins, C. R.; Bridges, T. M.; Gregory, K. J.; Niswender, C. M.; Conn, P. J. Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors. Chem. Rev. 2016, 116, 6707–6747.
(4) Emmette, K. A. mGlu, negative allosteric modulators: a patent review (2013–2016). Expert Opin. Ther. Pat. 2017, 27, 691–706.
(5) Rocher, J. P.; Bonnet, B.; Boléa, C.; Lüijens, R.; Le Pou, E.; Poli, S.; Epping-Jordan, M.; Bassis, A. S.; Ludwig, B.; Mutel, V. mGlu5 negative allosteric modulators: an overview. Curr. Top. Med. Chem. 2009, 9, 271–277.
(6) Mihov, Y.; Hasler, G. Negative allosteric modulators of metabotropic glutamate receptors subtype 5 in addiction: a therapeutic window. Int. J. Neuropsychopharmacol. 2016, 19, pyw002.
(7) Ribeiro, F. M.; Vieira, L. B.; Pires, R. G.; Olmo, R. P.; Ferguson, S. M.; Metabotropic glutamate receptors and neurodegenerative diseases. Pharmacol. Rev. 2017, 69, 179–191.
(8) Busse, C. S.; Brodkin, J.; Tattersall, D.; Anderson, J. J.; Warren, N.; Tehrani, L.; Bristow, L. J.; Varney, M. A.; Cosford, N. D. P. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-([2-methyl-1,3-thiazol-4-yl]ethyl)-pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 2004, 29, 1971–1979.
(9) Silverman, J. L.; Smith, D. G.; Rizzo, S. J.; Karras, M. N.; Turner, S. M.; Tohu, S. S.; Bryce, D. K.; Smith, D. L.; Fonseca, K.; Ring, R. H.; Crawley, J. N. Negative allosteric modulation of the mGlur5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci. Transl. Med. 2012, 4, 131ra51.
(10) Pop, A. S.; Gomez-Mancilla, B.; Neri, G.; Willensen, R.; Gasparini, F. Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGlur5) antagonists and drug development. Psychopharmacology (Berl) 2014, 231, 1217–1226.
(11) Litim, N.; Morissette, M.; Di Paolo, T. Metabotropic glutamate receptors as therapeutic targets in Parkinson’s disease: an update from the last 5 years of research. Neuropharmacology 2017, 115, 166–179.
(12) Rascol, O.; Fox, S.; Gasparini, F.; Kenney, C.; Di Paolo, T.; Gomez-Mancilla, B. Use of metabotropic glutamate 5 receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat. Disord. 2014, 20, 947–956.
(13) Jaso, B. A.; Niciu, M. J.; Iadarola, N. D.; Lally, N.; Richards, E. M.; Park, M.; Ballard, E. D.; Nugent, A. C.; Machado-Vieira, R.; Zarate, C. A. Therapeutic modulation of glutamate receptors in major depressive disorder. Curr. Neuropsychopharmacol. 2017, 15, 57–70.
(14) Rutrick, D.; Stein, D. J.; Subramanian, G.; Smith, B.; Fava, M.; Hasler, G.; Cha, J.; Gasparini, F.; Donchev, T.; Ocwieja, M.; Johns, D.; Gomez-Mancilla, B. Mavoglu enhancement in OCD patients resistant to selective serotonin reuptake inhibitors: a proof-of-concept, randomized, placebo-controlled, phase 2 study. Adv. Ther. 2017, 34, 524–541.
(15) Gasparini, F.; Lingenhöhl, K.; Stoehr, N.; Flor, P. J.; Heinrich, M.; Vranesc, I.; Biollaz, M.; Allgeier, H.; Heckendorn, R.; Uswelry, S.; Varney, M. A. S.; Johnson, E. C.; Hess, S. D. R.; Rao, S. P.; Sacan, A. I.; Santori, E. M.; Velocelevi, G.; Kuhn, R. Metaphosph-6-(phenethyl)pyridine (MPEP), a potent, selective and systematically active mGlur5 receptor antagonist. Neuropsychopharmacology 1999, 18, 1493–1503.
(16) Cosford, N. D.; Tehrani, L.; Roppe, J.; Schweiger, E.; Smith, N. D.; Anderson, J.; Bristow, L.; Brodkin, J.; Jiang, X.; McDonald, I.; Rao, S.; Washburn, M.; Varney, M. A. S. 3-([2-Methyl-1,3-thiazol-4-yl]ethyl)-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 2003, 46, 204–206.
(17) Porter, R. H. P.; Jaeschke, G.; Spooren, W.; Ballard, T. M.; Büttelmann, B.; Kolszewski, S.; Peters, J. U.; Prinssen, E.; Wichmann, J.; Vieira, E.; Mühlmann, A.; Gatti, S.; Mutel, V.; Malherbe, P. Fenobas: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlur5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 2005, 315, 711–721.
(18) Berry-Kravis, E. M.; Hess, D.; Coffey, S.; Hervey, C.; Schneider, A.; Yuhas, J.; Hutchinson, J.; Snape, M.; Tranflagia, M.; Nguyen, D. V.; Hagerman, R. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 2009, 46, 266–271.
(19) Swedberg, M. D. B.; Rabinovich, P. AZD9272 and AZD2066: selective and highly central nervous system penetrant mGlur5 antagonists characterized by their discriminative effects. J. Pharmacol. Exp. Ther. 2014, 350, 212–222.
(20) Stähle, L.; Karlsten, R.; Jonzon, B.; Eriksson, B.; Kågedal, M.; Dominicus, A. Safety evaluation of the mGlur5 antagonists AZD9272, AZD2066 and AZD9276.
AZD2066, and AZD2516 in healthy volunteers and patients with neuropathic pain or major depressive disorders. Abstract PT444. Proceedings of the 14th World Congress on Pain, Milan, Italy, August 28, 2012; International Association for the Study of Pain: Washington, DC, 2012.

(21) Vranesic, I.; Ofner, S.; Flor, P. J.; Bilbe, G.; Bouhebal, R.; Enz, A.; Desrayaud, S.; McAllister, K.; Kuhn, R.; Gasparini, F. AFGQ56/mavogluvant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. Bioorg. Med. Chem. 2014, 22, 5790–5803.

(22) Berry-Kravis, E.; Des Portes, V.; Hagerman, R.; Jacquemont, S.; Charles, P.; Visootsak, J.; Brinkman, M.; Rerat, K.; Koumaras, B.; Zhu, L.; Barth, G. M.; Jaecklin, T.; Apostol, G.; von Raison, F. Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci. Transl. Med. 2016, 8, 321ra5.

(23) Trenkwalder, C.; Stocchi, F.; Poeve, W.; Dronamraju, N.; Kenney, C.; Shah, A.; von Raison, F.; Graf, A. Mavoglurant in Parkinson’s patients with l-Dopa-induced dyskinesias: two randomized phase 2 studies. Mov. Disord. 2016, 31, 1054–1058.

(24) Tocchi, F.; Rascol, O.; Destee, A.; Hattori, N.; Hauser, R. A.; Lang, A. E.; Poeve, W.; Stacy, M.; Tolosa, E.; Gao, H.; Nagel, J.; Manka, J. T.; Byers, F. W.; Daniels, J. S.; Niswender, C. M.; Jones, C. K.; Conn, P. J.; Lindsley, C. W.; Emmitee, K. A. Discovery of VU0491753: a negative allosteric modulator of mGluR5, with activity in a mouse model of anxiety. Bioorg. Med. Chem. Lett. 2014, 24, 3307–3314.

(25) Walles, M.; Wolf, T.; Jin, Y.; Ritzau, M.; Leuthold, L. A.; Krauser, J.; Gschwind, H. P.; Carcache, D.; Kettelman, M.; Owcieja, M.; Ufer, M.; Woessner, R.; Chakraborty, A.; Swart, P. Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavogluvant (AFGQ56) in healthy subjects. Drug Metab. Dispos. 2013, 41, 1626–1641.

(26) Jaeschke, G.; Kolczews, S.; Spooren, W.; Vieira, E.; Bitter-Stoll, N.; Boissin, P.; Borroni, E.; Buettelmann, B.; Ceccarelli, S.; Clemann, S.; Clemmen, N.; David, B.; Funk, C.; Guba, W.; Harrison, A.; Hartung, T.; Honer, M.; Huwyler, J.; Kuratli, M.; Niederhauser, U.; Fuhl, A.; Peters, J. U.; Petersen, A.; Prinssen, E.; Ricci, A.; Ritter, D.; Ritter, M.; Schneider, M. Spurr, P.; Stoll, T.; Tannler, D.; Wichmann, J.; Porter, R. H.; Wettstein, J. G.; Lindemann, L. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-yl]pyridine (basinglumir, RO4917523), a promising novel medicine for psychiatric diseases. J. Med. Chem. 2015, 58, 1358–1371.

(27) Guerini, E.; Schadt, S.; Greig, G.; Haas, R.; Husser, C.; Zaleska, M. M.; Zasadny, K.; Shaffer, C. L. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-yl-methoxy)-1H-pyrazolo-[3,4-b]-pyridine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. J. Med. Chem. 2014, 57, 861–877.

(28) Zientek, M.; Miller, H.; Smith, D.; Dunklee, M. B.; Heinle, L.; Thurston, A.; Lee, C.; Hyland, R.; Fahmi, O.; Burdette, D. Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and perform colinear characterization of 1-methyl-3-(4-(6-methoxy)-1H-pyrazolo[3,4-b]-pyridine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. J. Med. Chem. 2014, 57, 861–877.

(29) Niswender, C. M.; Jones, C. K.; Conn, P. J.; Lindsley, C. W.; Emmitee, K. A. Discovery of VU0491753: a negative allosteric modulator of mGluR5, with activity in a mouse model of anxiety. Bioorg. Med. Chem. Lett. 2014, 24, 3307–3314.

(30) Zhou, Y.; Rodriguez, A. L.; Lavreysen, H.; Stauffer, S. R.; Niswender, C. M.; Jones, C. K.; Conn, P. J.; Lindsley, C. W.; Emmitee, K. A. Discovery of VU0409106: a negative allosteric modulator of mGluR5, with activity in a mouse model of anxiety. Bioorg. Med. Chem. Lett. 2013, 23, 5779–5785.

(31) Crouch, R. D.; Morrisson, R. D.; Byers, F. W.; Lindsley, C. W.; Emmitee, K. A.; Daniels, J. S. Evaluating the disposition of a mixed aldehyde oxycyclopropene P450 substrate in rats with attenuated P450 activity. Drug Metab. Dispos. 2016, 44, 1296–1303.

(32) Rook, J. M.; Tantawy, M. N.; Ansari, M. S.; Parn, A. S.; Staufer, S. B.; Emmitee, K. A.; Kessler, R. M.; Niswender, C. M.; Daniels, J. S.; Jones, C. K.; Lindsley, C. W.; Emmitee, K. A. Discovery of VU0409106: a negative allosteric modulator of mGluR5, with activity in a mouse model of anxiety. Bioorg. Med. Chem. Lett. 2013, 23, 5779–5785.
(61) Browne, C. A.; Lucki, I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. *Front. Pharmacol.* 2013, 4, 161.

(62) Zanos, P.; Moaddel, R.; Morris, P. J.; Georgiou, P.; Fischell, J.; Elmer, G. I.; Alkondon, M.; Yuan, P.; Pribut, H. J.; Singh, N. S.; Dossou, K. S.; Fang, Y.; Huang, X. P.; Mayo, C. L.; Wainer, I. W.; Albuerqueque, E. X.; Thompson, S. M.; Thomas, C. J.; Zarate, C. A., Jr.; Gould, T. D. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. *Nature* 2016, 533, 481–486.

(63) Pomierny-Chamiolo, L.; Polesak, E.; Pile, A.; Nowak, G. NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice. *Pharmacol. Rep.* 2010, 62, 1186–1190.

(64) Wang, D. F.; Waterhouse, R.; Kwonbura, H.; Kim, J.; Bräsi, J. R.; Chamroonrat, W.; Stabin, M. S.; Holt, D. P.; Dannals, R. F.; Hamill, T. G.; Mozley, P. D. 31F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. *J. Nucl. Med.* 2013, 54, 388–396.

(65) Conn, P. J.; Lindley, C. W.; Emmite, Kyle, A.; Rodriguez, A. L.; Fellts, A. S.; Jones, C. K.; Bates, B. S.; Chauder, B. A. 6-Alkyl-N-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGlur5 negative allosteric modulators and methods of making and using the same. U.S. Patent 9085562, July 21, 2015.